文献速递核素与放射性配体治疗肿瘤 PET/CT

个体化剂量学在90Y树脂微球选择性内放疗剂量调整中的关键作用

Key Role of Personalized Dosimetry in Dose Adjustment for Selective Internal Radiotherapy: Retrospective Study of Patients Treated With 90Y Resin Microspheres.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该回顾性研究纳入接受90Y树脂微球治疗的肝细胞癌患者,使用Simplicit90y软件进行剂量学分析,确定预测无进展生存的肿瘤剂量阈值。结果显示肿瘤剂量≥125 Gy的患者总生存和靶病灶进展时间显著优于<125 Gy者,基于99mTc-MAA SPECT/CT的个体化剂量学可预测疗效。

要点

  • 肿瘤剂量阈值125 Gy可预测靶病灶进展时间,灵敏度89%、特异度100%。
  • 肿瘤剂量≥125 Gy者中位OS 33个月,<125 Gy者仅7.5个月(P=0.002)。
  • 基于99mTc-MAA SPECT/CT的个体化剂量学有助于优化治疗计划。

核心结论

  • 基于99mTc-MAA SPECT/CT的个体化剂量学可预测肝细胞癌患者的靶病灶进展时间和总生存。
  • 定制剂量学软件对优化治疗计划至关重要。

研究设计与样本

  • 回顾性研究纳入接受90Y标记树脂微球治疗的肝细胞癌患者。
  • 使用Simplicit90y剂量学软件分析肿瘤和健康肝脏剂量。
  • 采用Kaplan-Meier法和log-rank检验评估靶病灶进展时间和总生存。

主要发现

  • 确定肿瘤剂量阈值125 Gy,灵敏度89%、特异度100%。
  • 肿瘤剂量<125 Gy者中位OS为7.5个月(95%CI 5-14个月),靶病灶进展时间为3个月(95%CI 2-6个月)。
  • 肿瘤剂量≥125 Gy者中位OS为33个月(95%CI 22-39个月),靶病灶进展时间为23个月(95%CI 7-38个月)。
  • 两组OS比较P=0.002,靶病灶进展时间比较P=0.0004。

关键数值与推荐

  • 肿瘤剂量阈值125 Gy用于预测靶病灶进展时间,灵敏度89%、特异度100%。

临床怎么用

  • 可利用基于99mTc-MAA SPECT/CT的个体化剂量学软件评估肿瘤剂量,辅助调整90Y树脂微球治疗计划。
  • 肿瘤剂量达到125 Gy或以上与更长的总生存和靶病灶进展时间相关。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Selective internal radiotherapy with 90Y microspheres is widely used for the treatment of patients with liver cancer. A dosimetric analysis using the dosimetry software Simplicit90y (Boston Scientific, Natick, MA) was conducted to define doses to the tumor and healthy liver, and to determine a threshold tumor dose that could predict progression-free survival. METHODS: Patients experiencing hepatocellular carcinoma and treated with 90Y-labeled resin microspheres were included in a retrospective study. The time-to-progression of the target lesions (TTPLs) and overall survival (OS) were evaluated using Kaplan-Meier tests, and this comparison was based on a log-rank test. RESULTS: Twenty-four procedures for patients with portal vein thrombosis were realized. Median follow-up was 16 months. A threshold tumor dose of 125 Gy was determined with a sensitivity of 89% and a specificity of 100%. For patients with a tumor dose of less than 125 Gy, the median OS was 7.5 months (95% confidence interval [CI], 5-14 months) and the TTPL was 3 months (95% CI, 2-6 months) versus 33 months (95% CI, 22-39 months) and 23 months (95% CI, 7-38 months), respectively, for those with a tumor dose of 125 Gy or more (P = 0.002 and P = 0.0004). CONCLUSIONS: Personalized dosimetry based on 99mTc-MAA SPECT/CT is predictive of TTPL and OS in patients with hepatocellular carcinoma. Customized dosimetry software is essential to optimize treatment planning.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Subreville C, Pinaquy JB, Lapuyade B, et al. Key Role of Personalized Dosimetry in Dose Adjustment for Selective Internal Radiotherapy: Retrospective Study of Patients Treated With 90Y Resin Microspheres. Clin Nucl Med. 2021. PMID: 34507332. doi:10.1097/RLU.0000000000003892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。